SENTI-202
Acute Myeloid Leukemia (AML)
Phase 1Active - Global clinical trial ongoing
Key Facts
Indication
Acute Myeloid Leukemia (AML)
Phase
Phase 1
Status
Active - Global clinical trial ongoing
Company
About Senti Biosciences
Senti Bio is developing next-generation cell and gene therapies by programming cells with synthetic biology-based Gene Circuits, designed to outsmart complex diseases with enhanced logic and control. The company has advanced its lead wholly-owned program, SENTI-202, into clinical trials for AML and maintains a broader preclinical pipeline targeting both liquid and solid tumors. Led by synthetic biology pioneers and experienced biotech executives, Senti aims to overcome limitations of current cell therapies by creating more intelligent, targeted medicines.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| NTLA-5001 | Intellia Therapeutics | Phase 1/2 |
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2/3 |
| SLS009 (GFH009) | SELLAS Life Sciences | Phase 1/2 |
| UCART123 | Cellectis | Phase 1 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |
| MP0533 | Molecular Partners | Phase 1/2 |
| SEL24 (MEN1703) | Selvita | Phase 1/2 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| NEX-20 (azacitidine) | Nanexa AB | Phase 1 |
| motixafortide (BL-8040) | BioLineRx | Phase 2a |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |